KD Logo

Trevi Therapeutics Inc [TRVI] Records 50-Day SMA of $2.72

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Trevi Therapeutics Inc shares valued at $136,110 were sold by SCIASCIA THOMAS on May 29 ’24. At $2.55 per share, SCIASCIA THOMAS sold 53,368 shares. The insider’s holdings dropped to 214,433 shares worth approximately $0.55 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Also, Delfini Lisa sold 4,350 shares, netting a total of over 11,485 in proceeds. Following the sale of shares at $2.64 each, the insider now holds 53,279 shares.

Before that, GOOD JENNIFER L had sold 25,037 shares from its account. In a trade valued at $71,576, the President & CEO traded Trevi Therapeutics Inc shares for $2.86 each. Upon closing the transaction, the insider’s holdings decreased to 25,037 shares, worth approximately $0.55 million.

As published in their initiating research note from Rodman & Renshaw on June 13, 2024, Trevi Therapeutics Inc [TRVI] has been a Buy and the price target has been revised to $7. Analysts at B. Riley Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in mid April. As of November 22, 2022, SVB Leerink has initiated its “an Outperform” rating for TRVI. Earlier on June 03, 2019, SVB Leerink initiated its rating. Their recommendation was “an Outperform” for TRVI stock.

Analyzing TRVI Stock Performance

During the last five days, there has been a drop of approximately -2.64%. Over the course of the year, Trevi Therapeutics Inc shares have jumped approximately 92.54%. Shares of the company reached a 52-week high of $4.00 on 03/21/24 and a 52-week low of $1.27 on 01/22/24. A 50-day SMA is recorded $2.72, while a 200-day SMA reached $2.18. Nevertheless, trading volume fell to 64317.0 shares from 0.16 million shares the previous day.

Support And Resistance Levels for Trevi Therapeutics Inc (TRVI)

According to the 24-hour chart, there is a support level at 2.57, which, if violated, would cause prices to drop to 2.46. In the upper region, resistance lies at 2.74. The next price resistance is at 2.80. RSI (Relative Strength Index) is 44.83 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.02, which suggests the price will decrease in the coming days. Percent R is at 65.82%, indicating low price movement. Stochastics%K at holding indicates that the stock is to be held.

Most Popular